As a result, due to its broad activity, resistance-evasion capacity, and brain penetration, NST-628 shows promise for treating a wide range of RAS- and RAF-driven CNS cancers, including those with KRAS, NRAS, or BRAF mutations [91]. This evidence concerns the gene RAF1 and central nervous system cancer.